BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

BeOne Medicines Ltd.

More Like This

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025